BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Wohl & Fruchter LLP Announces Investigation of Financial Misconduct at Jiangbo Pharmaceuticals, Inc. (Formerly known as Genesis Pharmaceuticals Enterprises, Inc.)


6/27/2011 7:02:03 AM

NEW YORK--(BUSINESS WIRE)-- The law firm of Wohl & Fruchter LLP announces that it has commenced an investigation into potential financial misconduct at Jiangbo Pharmaceuticals, Inc. (Jiangbo) (NASDAQ:JGBO - News).

Trading in Jiangbo’s common stock on The Nasdaq Global Market was halted on May 31, 2011.

According to a Form 8-K issued by Jiangbo on June 7, 2011, the independent members of Jiangbo’s audit committee announced their immediate resignations on June 6, 2011.

In a letter dated June 6, 2011, the audit committee members disclosed that Jiangbo had received a subpoena from the U.S. Securities and Exchange Commission on March 26, 2011, and that the audit committee had initiated an independent investigation in response, assisted by the law firm of Cadwalader, Wichersham & Taft (Cadwalader) and by Ernst & Young (China) Advisory Limited (E&Y).

The audit committee’s June 6 letter further disclosed that its independent members had made the decision to resign based on management’s “clear and continuing lack of cooperation” with their investigation, and further cited the manner and timing of the company’s payments to Cadwalader and E&Y as raising “additional serious concerns regarding the veracity or correctness of banking information provided by” Jiangbo’s management. Accordingly, the audit committee determined that it could no longer effectively conduct its investigation, and reported that Cadwalader and E&Y had withdrawn from their respective engagements.

Additional information is available at www.wohlfruchter.com/cases/jgbo.

Persons with relevant information, and shareholders with questions about this investigation, are invited to contact our Firm.

About Wohl & Fruchter

Wohl & Fruchter LLP represents plaintiffs in litigation arising from fraud and other fiduciary breaches by corporate managers, as well as other complex litigation matters. Please visit our website, www.wohlfruchter.com, to learn more about our Firm, or contact one of our partners.

This release may be deemed to constitute attorney advertising.

Contact:

Wohl & Fruchter LLPEthan Wohl, 212 758 4000Toll Free 866 582 8140ewohl@wohlfruchter.comwww.wohlfruchter.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES